Drug Trial Radar · NCT05345509
A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.
Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
62
Planned (sponsor's estimate)
Start
Apr 1, 2023
Primary completion
Nov 13, 2025
Study completion Nov 13, 2025
Sponsor
- Lead sponsor
- Inventage Lab., Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3003
Conditions
- Alzheimer Disease
Interventions
Aricept TabletDrug
Donepezil Tablet once daily P.O
IVL3003Drug
Donepezil Long-Acting Injection, once S.C Injection
IVL3003Drug
Donepezil Long-Acting Injection, once IM Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUClast of IVL3003Time frame: Pre-dose, up to 1month
- AUCinf of IVL3003Time frame: Pre-dose, up to 1month
- AUClast of AriceptTime frame: Pre-dose, up to 1month
- AUCinf of AriceptTime frame: Pre-dose, up to 1month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Melbourne, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.